Cargando…
Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline
QUESTIONS: 1. In patients with multiple myeloma, Waldenström macroglobulinemia, or lymphoma, what is the efficacy of bortezomib alone or in combination as measured by survival, quality of life, disease control (for example, time to progression), response duration, or response rate? 2. What is the to...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Multimed Inc.
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394599/ https://www.ncbi.nlm.nih.gov/pubmed/22792013 |